NCT06090799View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

March 28, 2024

Study Completion Date

April 8, 2024

Conditions
Prevention of Graft Rejection After Organ Transplantation
Interventions
DRUG

SHR-3032

Single dose at varying dosage levels depending on treatment assignment

DRUG

SHR-3032 Placebo

Single dose at varying dosage levels depending on treatment assignment

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

NCT06090799 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects | Biotech Hunter | Biotech Hunter